Classifications

• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
  • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
  • A23L27/30—Artificial sweetening agents
  • A23L27/33—Artificial sweetening agents containing sugars or derivatives
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
  • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
  • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
  • A23P10/00—Shaping or working of foodstuffs characterised by the products
  • A23P10/20—Agglomerating; Granulating; Tabletting
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
  • A23P10/00—Shaping or working of foodstuffs characterised by the products
  • A23P10/20—Agglomerating; Granulating; Tabletting
  • A23P10/25—Agglomeration or granulation by extrusion or by pressing, e.g. through small holes, through sieves or between surfaces
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
  • A23P10/00—Shaping or working of foodstuffs characterised by the products
  • A23P10/20—Agglomerating; Granulating; Tabletting
  • A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/06—Free radical scavengers or antioxidants
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

• the present invention relates to directly compressible compositions comprising more than 30% by weight of allulose, and to tablets obtainable thereof.
• Allulose is a hexoketose monosaccharide sweetener, which is a C-3 epimer of D-fructose and is rarely found in nature. It has 70% relative sweetness but 0.3% energy of sucrose, and is suggested as an ideal sucrose substitute for food products. It shows important physiological functions, such as blood glucose suppressive effect, reactive oxygen species scavenging activity, and neuroprotective effect. It also improves the gelling behavior and produces good flavor during food process.
• a non-cariogenic sweetener with a major component of allulose has been reported in literature to offer health benefits relevant to weight management and obesity related illnesses (i.e. type II diabetes, metabolic disorders).
• tablettes based on allulose, i.e., tablets comprising great amount of allulose, for use as a sweetener with health related benefits in confectionary products as well as nutritional and dietary supplement.
• Human or vetenary pharmaceutical solid dosage form could also take advantages of such excipient.
• the direct compression techniques enable the manufacture of tablets containing a precise amount of (active) ingredients, at high speed and at relatively low cost.
• Direct compression consists in strongly compressing a powder into a die using a punch, so as to impart thereto the form of a tablet.
• the high pressure applied allows aggregation of the molecules of the powder which produces a solid tablet.
• These powders include various ingredients, usually:
• Diluents also called “direct compression excipients” for the reason that they are the major compounds in the tablets and are responsible for the flow properties and compressibility of the powder to be compressed;
• glidants whose role is to promote the flow of the powder within the equipment used for tableting;
• pH stabilizing agents colorants, flavors, surfactants.
• Direct compression excipients are anhydrous lactose, cellulose and microcrystalline cellulose (MCC).
• MMC microcrystalline cellulose
• Direct compression excipients are the major ingredients in these compositions, as their role and their quantities are of importance in these compositions. They must be in large amounts to allow the obtaining of a solid dosage form.
• the inventors prepared allulose capable of acting as a direct compression excipient, and as a result, that can be introduced in significant amounts in tablets.
• the allulose according to the invention can advantageously fill both roles of sweetener and direct compression excipient.
• allulose is not naturally compressible; meaning that allulose obtained by natural crystallization in water is not compressible. It lacks flow, cohesion or lubricating properties necessary for the production of tablets by direct compression.
• the allulose developed by the inventors is in the form of granules, is compressible, and allows the preparation of tablets having hardness greater than 50 N.
• the invention thus first relates to granules of allulose which are compressible in the sole presence of a lubricant, to form a tablet having a diameter of 13 mm, a thickness of 6 mm, an apparent density of 1.35 g/ml ⁇ 0.02 g/ml, a cylindrical shape with convex faces with a radius of curvature of 13 mm, whose hardness is greater than 50 N.
• the present invention also relates to the use of granules of allulose according to the invention as a direct compression excipient in a directly compressible composition.
• the present invention also relates to a directly compressible composition comprising the granules of allulose according to the invention.
• the present invention also relates to a method for the manufacture of granules of allulose according to the invention, comprising:
• the present invention further relates to a method for the manufacture of a tablet, comprising the steps of: providing a directly compressible composition according to the invention; followed by directly compressing said composition to form the tablet.
• the present invention finally relates to a tablet composed of a directly compressible composition according to the invention, or obtained by the method for the manufacture of a tablet according to the invention.
• compositions based on allulose, suitable for direct compression as evidenced in Example 1.
• These directly compressible compositions allowed the preparation of tablets having hardness greater than 50 N. They comprised 99% by weight of allulose, and no other direct compression excipient was required to obtain these results.
• This allulose was obtained through a process of granulation that can be advantageously carried out by solely using water and allulose.
• Granulation refers to the act or process in which primary powder particles are made to bind each other to form multiparticulate agglomerates called granules. It is the process of collecting particles together by creating bonds between them.
• the two principal types of granulation technologies are wet granulation and dry granulation.
• granules are formed by the addition of a granulation liquid onto a powder bed which is under the influence of an impeller (in a High or Low shear granulator), screws (in a twin screw granulator), a rotating device (for instance a rotating pan or a rotating drum), or even preferably, air (in a fluidized bed granulator or in a spray-drier).
• the agitation and the wetting of the primary powder along the system results in the aggregation of the particles composing said primary powder to produce wet granules.
• the granulation liquid is removed by drying.
• the granulation liquid can be water-based or solvent-based. Typical solvents include water, ethanol and isopropanol either alone or in combination.
• the granulation liquid mixed into the powders can form bonds between powder particles that are strong enough to lock them together. However, once the liquid dries, the powders usually fall apart.
• Granulation process thus can be very complex depending on the characteristics of the powders, and the final objective.
• the liquid is not strong enough to create and hold a bond. In such instances, one or more binders are required.
• the one or more binders to be selected will strongly depend on the material to be made compressible, and to the granulation process used. Depending on the method, the one or more binders will be introduced at different time during the process. It can be introduced dissolved in suitable solvent or in the form of a powder that will dissolve in the granulation liquid during the process.
• binders are povidone, microcrystalline cellulose (MCC), carboxymethyl cellulose (CMC), hydroxypropyl cellulose (HPMC), starch derivatives like maltodextrins, acacia gum, tragacanth gum, gelatin.
• Povidone which is a polyvinyl pyrrolidone (PVP)
• PVP polyvinyl pyrrolidone
• the use of a binder is not sufficient, and the powder needs to be pre-treated before to be granulated, typically by undergoing a step of spray-drying.
• Example 1 Surprisingly, and as evidenced in Example 1, the inventors found that the compressible granules of allulose according to the invention could be obtained through particular process of wet granulation, by using allulose itself as a binder.
• the granulation liquid is advantageously water-based, so has the advantage of being safe to deal with.
• tablets comprising significant amounts of allulose, which can be greater than 30% by weight relative to the total weight of the tablet, typically of between 90 and 99%.
• Allulose can advantageously play both role of direct compression excipient and sweetener in the compositions of the present application.
• the granules of allulose according to the invention are particularly advantageous for both manufacture of suckable and chewable sweet tablets. Indeed, the tablets obtained out of the granules of allulose according to the invention exhibit excellent taste and texture, as compared to the sweet tablets of prior art, in particular as compared to the tablets made out of directly compressible sweet sugar or sugar alcohol of prior art. These tablets exhibit smooth sensation in the mouth when sucking, with no sticking and no gritty sensation, as well as pleasant chewable texture.
• Granules of allulose according to the invention are compressible in the sole presence of a lubricant, to form a tablet having a diameter of 13 mm, a thickness of 6 mm, an apparent density of 1.35 g/ml ⁇ 0.02 g/ml, a cylindrical shape with convex faces with a radius of curvature of 13 mm, whose hardness is greater than 50 N, preferably greater than 60 N, preferably greater than 70 N, preferably greater than 80 N, preferably greater than 90 N, preferably greater than 100 N, even more preferably greater than 110 N.
• the material to be compressed can be for instance composed of 99.0% by weight of said material and 1.0% of lubricant, usually magnesium stearate.
• the tablet can be formed by means of a single punch press, for instance like the one disclosed in “Procedure 1” hereinafter in the Examples.
• the hardness can be evaluated by the person skilled in the art on a hardness tester.
• An example of such hardness tester is disclosed in “Procedure 1” described hereinafter in the Examples.
• the value given in newtons usually corresponds to a mean value from 10 measurements.
• the hardness is lower than 800 N, even lower than 400 N, even lower than 300 N, even lower than 200 N, even lower than 150 N.
• the granules of allulose according to the invention preferably has mean volume diameter D 4,3 between 100 and 1000 ⁇ m, preferably between 150 and 800 ⁇ m and more preferably between 200 and 500 ⁇ m.
• the mean volume diameter D 4,3 can be determined by the person skilled in the art on a LASER diffraction granulometer type LS 230 from the company BECKMAN-COULTER, equipped with its powder dispersion module (dry method), following the manufacturers technical manual and specifications.
• the measurement range of the LASER diffraction granulometer type LS 230 is from 0.04 ⁇ m to 2000 ⁇ m.
• the operating conditions of hopper screw speed and intensity of vibration of the dispersion channel are determined in such a way that the optical concentration is between 4% and 12%, ideally 8%.
• the results are calculated in percentage by volume, and expressed in ⁇ m.
• Allulose used according to the invention can be in either the D- or L-configuration, however D-allulose is preferred in the present invention, because easier to obtain.
• the granules of allulose according to the invention can be used as a direct compression excipient in a directly compressible composition.
• directly compressible composition means a powdery composition suitable, per se, for the manufacture of tablets by direct compression.
• This composition always comprises a direct compression excipient or a mixture of direct compression excipients.
• Such composition allows the manufacture of tablets of sufficient hardness, and of satisfying appearance.
• the granules of allulose of the invention are further used as a sweetener, preferably as a low-calorie sweetener, i.e. for the manufacture of tablets having calorific value lower than 5 kcal/g, preferably lower than 4 kcal/g, preferably lower than 3 kcal/g, preferably lower than 2 kcal/g, even more preferably lower than 1 kcal/g.
• a sweetener preferably as a low-calorie sweetener, i.e. for the manufacture of tablets having calorific value lower than 5 kcal/g, preferably lower than 4 kcal/g, preferably lower than 3 kcal/g, preferably lower than 2 kcal/g, even more preferably lower than 1 kcal/g.
• sweetener having a relative sweetness, as compared to sucrose, of between 0.5 and 1.0, preferably of between 0.6 and 0.8, typically of 0.7.
• the granules of allulose of the invention are further used as a health ingredient having physiological functions, such as blood glucose suppressive effect, reactive oxygen species scavenging activity, and/or neuroprotective effect.
• the directly compressible compositions according to the invention can comprise significant amounts of allulose, notably without requiring the adding of other direct compression excipients.
• granules of allulose preferably represent at least 30% of the directly compressible composition, preferably at least 40%, preferably at least 50%, preferably at least 60%, preferably at least 70%, preferably at least 80%, preferably at least 90%, typically between 90 and 99%, even between 95 and 99%, said percentage being expressed in dry weight, with respect to the total dry weight of said directly compressible composition.
• the directly compressible compositions according to the invention comprises no more than 60% of direct compression excipients other than the granules of allulose according to the invention, preferably no more than 50%, preferably no more than 40%, preferably no more than 30%, preferably no more than 20%, preferably no more than 10%, preferably no more than 5%, more preferably no more than 2%, and most preferably 0%, said percentage being expressed in dry weight, with respect to the total dry weight of said directly compressible composition.
• step (a) simply consists in dissolving powdery allulose into water, to obtain an aqueous solution of allulose.
• Powdery allulose can be, for instance, individual crystals, classically obtained by crystallization from a solvent such as water or a mixture of water and ethanol, preferably water alone.
• Powdery allulose can also be composed of, or can also comprise, the granules obtained in step (c) or (c′), which are preferably grinded before undergoing step (b).
• Step (a) is preferably performed at a temperature which allows good dissolving of allulose into water. It is preferably performed at ambient temperature as allulose is very soluble in water (about 225 g per 100 ml water at 20° C.). For the preparation of a granulation liquid comprising higher concentrations of allulose, a heating will be required. Typically the allulose will be dissolved in water heated from 85° C. to 100° C.
• the granulation liquid is applied by means of a spraying system, for instance by using one or more spraying nozzle(s). It is preferably applied in the form of fine droplets.
• the quality of the contact between the granulation liquid and the powdery allulose during step (b) notably depends on the mean used to move the powdery allulose. This can be performed by subjecting the powder to the influence of an impeller (in a High or Low shear granulator), screws (in a twin screw granulator), a rotating device (for instance a rotating pan or a rotating drum), or even preferably, air (in a fluidized bed granulator or in a spray-drier).
• an impeller in a High or Low shear granulator
• screws in a twin screw granulator
• a rotating device for instance a rotating pan or a rotating drum
• air in a fluidized bed granulator or in a spray-drier
• step (c) is preferably performed concomitantly to the granulation step (b), by way of a granulator using air for granulation and for drying like spray-driers or fluidized bed granulators and dryers.
• the method for the manufacture of granules of allulose according to the invention is preferably a continuous process using in particular a mixer-granulator, a continuous fluid bed granulator, or a spray-dryer.
• the continuous process preferably includes the recycling of the granules obtained in step (c) or (c′).
• the granules are preferably grinded before undergoing step (b).
• the amount of recycled granules can be adapted so as to optimize the crystallization of allulose, to prevent the excessive formation of amorphous allulose.
• the ratio by weight of granulation liquid to the recycled granules is thus preferably of between 1:2 and 1:15, preferably of between 1:4 and 1:10.
• the continuous process can be performed in an spray-dryer preferably equipped with a high pressure spray-drying nozzle, for instance of MSD-type, which preferably comprises the recycling of particles in the drying chamber.
• Granulation may be carried out using, for example, a mixer-granulator operating batchwise, semi-continuously or continuously such as the vertical FLEXOMIX marketed by SCHUGI, a device of the DRIAM or DUMOULIN type, or the horizontal CB marketed by LODIGE into which is introduced, by way of a weight feeder, the starting powdery allulose to be granulated continuously and the granulation liquid by way of a volumetric feeder.
• a mixer-granulator operating batchwise, semi-continuously or continuously such as the vertical FLEXOMIX marketed by SCHUGI, a device of the DRIAM or DUMOULIN type, or the horizontal CB marketed by LODIGE into which is introduced, by way of a weight feeder, the starting powdery allulose to be granulated continuously and the granulation liquid by way of a volumetric feeder.
• the starting powdery allulose and the granulation solution are very intimately mixed in the mixer-granulator fitted with a shaft with knives arranged in the form of blades, and a system of spraying liquids by way of injection nozzles.
• satisfactory dispersion of the constituents and agglomeration of the particles of the starting powdery allulose are carried out by high speed stirring, i.e. at a value at least equal to 1000 rpm, preferably at least equal to 3500 rpm.
• the granules formed are discharged continuously into a dryer-ageing device.
• Discharge takes place preferably by gravity in the case of said vertical granulator, and by thrust by way of the shaft of rotating knives if the horizontal granulator is used.
• This second drying-ageing step at the outlet of the mixer-granulator makes it possible to remove, if necessary, all or part of the water originating from the binder such that crystallization and stabilization take place after the prior granulation step.
• the dryer-ageing device may be, for example, a fluidized bed dryer-ageing device or a rotary ageing drum.
• the allulose according to the invention is obtained after cooling and optionally sieving.
• the fine particles may be recycled directly to the start of granulation, and the coarse particles may be ground and recycled to the start of sieving.
• Granulation can be performed in a high shear granulator, using a high speed propeller and a chopper to avoid too big lumps to be created.
• Such high shear granulators are very common in the pharmaceutical industry and manufactured by well-known suppliers (GLATT, DIOSNA, IMA and the like). Using such equipment the drying step (c) has to be done after the granulation step (b).
• fluidized bed granulators (GLATT, GEA and the like) enable to do granulation step (b) and drying step (c) concomitantly.
• step (a) the starting allulose is in general the same as the one used in the moving powdery allulose.
• Optional step (c′) can be performed to allow granules to further crystallization and stabilization at a controlled temperature.
• This step (c′) is preferably performed in a fluid bed or in a rotary drum.
• the granules of allulose according to the invention may comprise other ingredients, as long as it does not negatively affect the desired properties of the granules.
• the other ingredients are generally introduced in the process of manufacture of granules of allulose according to the invention, via the granulation liquid or via the moving powdery allulose.
• Such ‘other ingredients’ can be without limitation:
• the granules preferably contain substantially no binders, other than allulose.
• the total amount of ‘other ingredients’ will be lower than 80%, preferably lower than 40%, preferably lower than 10%, preferably lower than 5%, most preferably equal to 0%, said percentage being expressed in dry weight, with respect to the total dry weight of said granules.
• the allulose such as defined in the present invention generally has purity between 95.0 and 99.9%, said percentage being expressed in dry weight of allulose with respect to the total dry weight of said allulose
• the purity can in particular be determined by the person skilled in the art by using HPLC method with calcium column.
• tablette means any solid edible preparation, which is obtained by direct compression.
• These tablets can be in the form of suckable tablets like mints, or in the form of soft or hard chewable tablets. They can be normal or multi layers tablets. They can be used as a nutritional or dietary supplement, or as a pharmaceutical, and can be intended for humans, adults or children, or to animals.
• the tablet is a sweet tablet, having calorific value lower than 5 kcal/g, preferably lower than 4 kcal/g, preferably lower than 3 kcal/g, preferably lower than 2 kcal/g, even more preferably lower than 1 kcal/g.
• It preferably has a relative sweetness, as compared to sucrose, of between 0.5 and 1.0, preferably of between 0.6 and 0.8, for example of 0.7.
• the tablet according to the invention has hardness greater than 50 N, preferably greater than 60 N, preferably greater than 70 N, preferably greater than 80 N, preferably greater than 90 N, preferably greater than 100 N, preferably greater than 110 N.
• the hardness of the tablet is lower than 800 N, even lower than 700 N, even lower than 600 N, even lower than 500 N, even lower than 400 N, even lower than 300 N, even lower than 200 N, even lower than 150 N.
• the tablets according to the invention can be coated, notably by regular spray-drying of a film-forming composition onto a moving bed of tablets.
• the coating layer in general, will not exceed 5% in weight of the coated tablet.
• the tablets may also be coated with sugars or polyols, using a “sugar-coating” process to form a frosting or a soft or hard coating, depending on the amount of powders or the coating process used.
• compositions and the tablets according to the invention generally comprise other ingredients.
• other ingredients can be without limitation:
• compositions composed of 99.0% by weight of the material to be tested as a direct compression excipient and 1.0% by weight of magnesium stearate were first prepared.
• Tablets were prepared out from these compositions, by means of the single punch laboratory press FROGERAIS AM (SVIAC, Anthony, France).
• These tablets had a diameter of 13 mm, a thickness of 6 mm, an apparent density of 1.35 OA ⁇ 0.02 g/ml, and a cylindrical shape with convex faces with a radius of curvature of 13 mm.
• the inventors measured the hardness of the tablets thus obtained on an ERWEKA TBH 30 GMD hardness tester (ERWEKA, Heusenstamm, Germany). The value given in
• Newtons corresponds to a mean value from 10 measurements.
• Example 1 Preparation of Granules of Allulose According to the Invention Using a Batch Fluid Bed Granulator
• Granules of allulose were prepared in a fluid bed granulator Strea-1 (Aeromatic_Fielder/GEA—Bubendorf Switzerland).
• a solution of allulose is prepared by dissolving 25 g of allulose in 125 ml of water. This solution is sprayed on 300 g of powdery allulose fluidized in the fluid bed granulator.
• the allulose powder used has a mean diameter of 85 ⁇ m.
• the fluidizing air entrance is at 60° C. and the outlet air at 35° C. This solution is added during 15 minutes (spraying speed about 10 ml per minute).
• the drying (air at 60° C.) is pursued about 30 minutes after the end of the spraying so that the powder is sufficiently dried.
• the granules obtained are sieved between 100 ⁇ m and 1000 ⁇ m to remove the fine and coarse particles, to give granules [i-A].
• Example 2 Preparation of Granules of Allulose According to the Invention Using a Rotating Pan Granulator
• Allulose granules were prepared using home-made rotating pan granulator.
• An allulose solution was prepared by dissolving 450 g of allulose crystal in 50 g water at a temperature of 85 to 100° C. The solution was sprayed, with compressed air nozzle, on allulose dry powder in a rotating pan with a ratio of liquid to powder at 1:4. The liquid spray rate was about 7.5 ml per minute. The liquid temperature was maintained at 90° C. during the process.
• Granules of allulose of a few millimeters were formed and continuously discharged out of rotating pan while the volume in the pan remains at constant. The granules were dried and maturated at forced-air circulation oven at 75° C. for 2 hours and conditioned at ambient temperature for 4 hours. The granules were then grinded and sieved at desired particle size of between 100 and 1000 ⁇ m to give granules [i-B].
• the inventors succeeded for the first time in obtaining directly compressible allulose, allowing the preparation of tablets having hardness greater than 50 N, in the sole presence of a lubricant, in particular in the present case, from compositions composed of 99.0% by weight of granules of allulose according to the invention and 1.0% by weight of magnesium stearate.
• the tablets thus obtained exhibited excellent taste and texture. They showed particularly smooth sensation in the mouth when sucking, with no sticking and no gritty sensation, as well as particularly pleasant chewable texture.

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Polymers & Plastics (AREA)
• Food Science & Technology (AREA)
• Nutrition Science (AREA)
• Molecular Biology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Mycology (AREA)
• Diabetes (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biochemistry (AREA)
• Neurology (AREA)
• Toxicology (AREA)
• Hematology (AREA)
• Endocrinology (AREA)
• Emergency Medicine (AREA)
• Biomedical Technology (AREA)
• Obesity (AREA)
• Neurosurgery (AREA)
• Medicinal Preparation (AREA)
• General Preparation And Processing Of Foods (AREA)
• Seasonings (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=51265637

Family Applications (3)

Family Applications After (2)

Country Status (11)

Cited By (2)

Families Citing this family (3)

Family Cites Families (19)

• 2015
  • 2015-07-16 BR BR112017001000-3A patent/BR112017001000B1/pt active IP Right Grant
  • 2015-07-16 CA CA2955845A patent/CA2955845C/en active Active
  • 2015-07-16 SG SG11201700445YA patent/SG11201700445YA/en unknown
  • 2015-07-16 KR KR1020177000682A patent/KR102557664B1/ko active IP Right Grant
  • 2015-07-16 JP JP2017503616A patent/JP6731400B2/ja active Active
  • 2015-07-16 EP EP15778703.7A patent/EP3171709B1/en active Active
  • 2015-07-16 US US15/325,030 patent/US20170208849A1/en not_active Abandoned
  • 2015-07-16 CN CN201580039976.2A patent/CN106659225B/zh active Active
  • 2015-07-16 MX MX2017000829A patent/MX2017000829A/es unknown
  • 2015-07-16 WO PCT/IB2015/001302 patent/WO2016012853A1/en active Application Filing
• 2017
  • 2017-01-19 CL CL2017000153A patent/CL2017000153A1/es unknown
• 2018
  • 2018-11-30 US US16/205,696 patent/US11350658B2/en active Active
• 2022
  • 2022-04-14 US US17/720,656 patent/US11986002B2/en active Active

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events